Wall Street Zen upgraded shares of Atrinsic (NASDAQ:PTIX – Free Report) from a sell rating to a hold rating in a research report report published on Saturday.
Atrinsic Price Performance
Shares of PTIX stock opened at $3.34 on Friday. The firm has a 50-day moving average of $3.26 and a 200-day moving average of $3.63. The company has a market cap of $1.97 million, a P/E ratio of -0.35 and a beta of 0.36. Atrinsic has a one year low of $2.25 and a one year high of $15.26.
Atrinsic (NASDAQ:PTIX – Get Free Report) last announced its earnings results on Wednesday, September 10th. The company reported ($1.37) EPS for the quarter.
About Atrinsic
Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
Featured Stories
- Five stocks we like better than Atrinsic
- What to Know About Investing in Penny Stocks
- Reddit Hits Record Highs: Why Wall Street Is Taking Notice
- Large Cap Stock Definition and How to Invest
- After a Strong Wall Street Debut, Klarna’s Real Work Begins
- Roth IRA Calculator: Calculate Your Potential Returns
- 3 Dividend Growers That Fly Under the Radar
Receive News & Ratings for Atrinsic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrinsic and related companies with MarketBeat.com's FREE daily email newsletter.
